医师改造型腔内移植物治疗复杂主动脉病变的患者生存率与靶内脏血管相关结局与工厂定制开窗移植物相似
该研究基于血管质量倡议(VQI)2014至2022年数据,排除后纳入544例医师改造开窗移植物(PMEG)和1638例工厂定制开窗移植物(FMFE),比较内脏支架分支相关结局和患者生存。PMEG组合并症更多、平均支架内脏血管数更多(3.48 vs 3.01,P<0.001),但两组死亡、新发透析、内脏缺血无显著差异;内脏支架再干预在多变量Cox回归中无显著差异(HR 1.25,P=0.406)。
要点
- PMEG组合并症更重,平均支架内脏血管数3.48 vs FMFE组3.01(P<0.001)。
- 两组死亡、新发透析、内脏缺血无显著差异。
- 内脏支架再干预多变量Cox回归无显著差异(HR 1.25,P=0.406)。
核心结论
- 医师改造开窗内脏段腔内移植物与定制FMFE相比,中期无死亡生存、无内脏支架再干预、无新发透析和无肠缺血结局相似,尽管PMEG患者合并症显著更多、受累内脏血管更多且夹层相关动脉瘤更多。
研究设计与样本
- 研究为真实世界比较,基于血管质量倡议(VQI)2014至2022年数据,排除后纳入544例PMEG和1638例FMFE。
- 采用Kaplan-Meier分析四个主要结局:无死亡生存、新发透析、内脏缺血和随访期内脏支架再干预。
- 对随访期内脏再干预行多变量Cox回归,纳入单变量P<0.10的变量。
- 比较PMEG与FMFE组基线人口学和合并症,并分析围手术期不良结局的单变量风险。
主要发现
- PMEG组动脉瘤更大、平均支架内脏血管数更高、高血压、贫血、既往冠状动脉血运重建、既往开放主动脉手术及内脏靶动脉狭窄大于50%的比例更高(所有P<0.01)。
- PMEG组因主动脉夹层原发病理干预的比例为9.7%,FMFE组为2.3%(P<0.001),PMEG组高3倍。
- 生存平均随访时间PMEG组1.9年,FMFE组3.0年;内脏支架相关数据平均随访时间PMEG组1.07年,FMFE组1.19年。
- 随访中PMEG与FMFE组在死亡、新发透析或肠缺血方面无显著差异。
- 单变量Kaplan-Meier分析显示PMEG组无内脏支架分支再干预率更高(log rank P=0.002),但多变量Cox回归因PMEG组平均治疗分支数显著更多(3.48 vs 3.01,P<0.001)而变为无显著差异(HR 1.25,P=0.406);与内脏支架再干预相关的唯一多变量显著变量是平均支架血管数(HR 2.15,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to conduct a real-world comparison of visceral stent branch related outcomes and patient survival in physician-modified endografts (PMEGs) versus factory-made fenestrated endografts (FMFEs). METHODS: After exclusions, 544 PMEG and 1638 FMFE were identified in the Vascular Quality Initiative between 2014 and 2022. The four primary outcomes analyzed with Kaplan-Meier were freedom from mortality, new onset dialysis, visceral ischemia, and visceral stent-graft reintervention in follow-up. Multivariable Cox regression was also performed for visceral reintervention in follow-up utilizing variables with a univariable P < 0.10. Comparison of baseline demographics and co-morbidities in the PMEG versus FMFE group were performed as was univariable risks for perioperative adverse outcomes. RESULTS: PMEG patients were a more comorbid cohort highlighted by: larger aneurysms; higher mean number of visceral vessels stented; higher rates of hypertension, anemia, prior coronary revascularization, prior open aortic surgery, and greater than 50% stenosis in one of the visceral target arteries (P < 0.01 for all). Further, PMEG patients had a 3-fold higher rate of intervention for a primary pathology of aortic dissection (9.7% vs. 2.3%, P < 0.001). Mean follow-up for survival was 1.9 years for PMEG and 3.0 years for FMFE. Mean follow-up for visceral stent-related data was 1.07 and 1.19 years for PMEG and FMFE, respectively. There was no significant difference between the PMEG and FMFE groups in mortality, new onset dialysis or intestinal ischemia in follow-up. Univariable Kaplan-Meier analysis for freedom from visceral stent branch reintervention showed an increased rate for PMEG (log rank P = 0.002). However, multivariable Cox regression rendered this nonsignificant (hazard ratio [HR] 1.25, P = 0.406) due to significantly more branches being treated on average in the PMEG group (3.48 vessels versus 3.01, P < 0.001). The only variable which achieved multivariable significance in association with visceral stent reintervention was the mean number of vessels stented (HR 2.15, P < 0.001). CONCLUSION: Physician-modified fenestrated visceral segment endografts achieve similar mid-term freedom from mortality, visceral stent-graft reintervention, new onset dialysis, and intestinal ischemia relative to custom FMFEs. This is despite PMEG patients being a significantly more comorbid cohort, with more visceral vessels involved and more dissection related aneurysms.
引用
- Soult M, Chawla K, Ganeshan N, et al. Physician-Modified Endografts Achieve Similar Patient Survival and Target Visceral Vessel Related Outcomes to Factory-Made Fenestrated Endografts in Treating Complex Aortic Pathology. Ann Vasc Surg. 2025. PMID: 40064289. doi:10.1016/j.avsg.2025.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。